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In the present work, we have analyzed the antigenicity of Leishmania species ribosomal proteins (LRPs). To
accomplish this, Leishmania infantum ribosomes were biochemically purified from promastigote cytosolic
extracts, and their reactivities were analyzed by using the sera from dogs naturally infected with L. infantum.
Since antibodies reacting against different ribosomal proteins were observed in all the serum samples obtained
from dogs with symptomatic visceral leishmaniasis tested, we have analyzed the potential usefulness of the
LRP extracts in the development of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of
canine visceral leishmaniasis (CVL) in an area of Brazil where visceral leishmaniasis is endemic due to
infection by Leishmania chagasi. A comparative ELISA with crude soluble Leishmania chagasi antigen (SLA)
and L. infantum LRPs was performed. LRP- and SLA-based ELISAs gave similar sensitivities for the diagnosis
of symptomatic CVL, but the LRP extract provided a very high sensitivity for the detection of oligosymptomatic
and asymptomatic dogs. In addition, an LRP-based ELISA showed a higher specificity when the sera from dogs
harboring other infections were included in the analysis. The LRP antigen displayed no cross-reactivity with
sera from dogs that had any of the other diseases tested, notably, Chagas’ disease. Our findings suggest that
LRPs are a potential tool for the diagnosis of CVL and will be particularly useful for the diagnosis of
asymptomatic CVL.
Canine visceral leishmaniasis (CVL) is an important emerg-
ing zoonosis in countries around the Mediterranean Basin, the
Middle East, and Latin America (26). This severe disease is
caused by Leishmania infantum in the Mediterranean area and
in the Middle East and Asian countries and is caused by
Leishmania chagasi in Latin America (26, 27). Due to their
genotypic relationships, both species causing CVL in different
continents can be considered to be identical (32).
Upon infection, dogs can develop different forms of the
disease: asymptomatic, oligosymptomatic, or symptomatic (5).
Symptomatic infection results in death; and its clinical mani-
festations include cutaneous alterations, such as alopecia, der-
matitis, and onychogryphosis (4, 16), and also visceral mani-
festations with splenic, renal, hepatic, and cerebral alterations
(22, 37). However, some of the infected dogs remain asymp-
tomatic or develop a few mild symptoms and are classified as
oligosymptomatic (5). CVL cannot be considered only a vet-
erinary disease, since infected dogs (even asymptomatic ones)
are the main domestic reservoir of the parasite for human
infection (2). Thus, to reduce the frequency of transmission of
Leishmania from dogs to humans, it is necessary to diagnose
canine leishmaniasis as early as possible (35).
The presence of anti-Leishmania-specific antibodies in
asymptomatic, oligosymptomatic, and symptomatic infected
dogs (5, 12, 45) has allowed the development of serologic
tests, including immunofluorescent antibody tests, Western
blotting, immunochromatographic tests, and enzyme-linked
immunosorbent assays (ELISAs) (for a review, see reference
29). The diagnosis of CVL by ELISAs based on crude soluble
Leishmania antigens (SLAs) have shown a high degree of sen-
sitivity but a low degree of specificity because of the antigenic
relatedness of Leishmania and other pathogenic protozoa (21).
As a strategy for the development of specific serodiagnostic
tests for CVL, different parasite antigens were obtained as
recombinant proteins (23, 30, 48). However, due to the high
degree of variability in the humoral responses to different
parasite antigens observed in infected dogs (24, 42), the effi-
cient diagnosis of CVL based on recombinant proteins may
require a mixture of recombinant proteins or the use of chi-
merical proteins containing several nonrelated parasite anti-
gens (7, 42, 49). The specific diagnosis of CVL can also be
developed by using preparations purified from the parasite
(6, 9) or crude parasite fractions analyzed by Western blotting
(1, 20).
Some of the parasite ribosomal constituents, such as the
parasite acidic P proteins, induce strong humoral responses in
dogs clinically infected with L. infantum (46). In addition,
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Leishmania ribosomal proteins (LRPs) seem to be immuno-
logically relevant molecules during murine experimental cuta-
neous leishmaniasis because high titers of antibodies recogniz-
ing the parasite ribosomal proteins were detected in sera from
BALB/c mice infected with L. major (28). Here, we show that
sera from dogs naturally infected with L. infantum showed
reactivity against different ribosomal proteins by Western blot-
ting. In addition, a serological evaluation of LRPs by ELISA
with these sera revealed that LRP-based assays have a sensi-
tivity similar to that of SLA-based assays for the diagnosis of
symptomatic CVL. Thus, the ELISA technique was used to
evaluate the diagnostic potential of LRP extracts in compari-
son with that of SLAs by using sera from asymptomatic, oli-
gosymptomatic, and symptomatic L. chagasi-infected dogs as
well as dogs infected with other protozoan parasites. We con-
clude that the ELISAs with LRPs have a better sensitivity and
a higher specificity than the SLA-based assays for the diagnosis
of CVL.
MATERIALS AND METHODS
Parasites. Leishmania chagasi (MOM/BR/1970/BH46) and L. infantum
(MCAN/ES/1996/BCN/150/MON-1) were grown at 24°C in Schneider’s medium
(Sigma, St. Louis, MO) supplemented with 20% heat-inactivated fetal bovine
serum (Sigma), 20 mM L-glutamine, 200 U/ml penicillin, 100 g/ml streptomycin,
and 50 g/ml gentamicin at pH 7.4.
Antigen preparation. SLA was prepared from stationary-phase promastigotes
of L. chagasi and L. infantum, as described previously (17). Briefly, 2  108
promastigotes per ml, in a volume of 5 ml, were washed three times in cold sterile
phosphate-buffered saline (PBS). After six cycles of freezing and thawing fol-
lowed by ultrasonication (GEX600 ultrasonic processor) by the use of five cycles
of 30 s at 38 MHz, the suspension was centrifuged at 8,000  g for 30 min at 4°C
and the supernatant containing the SLA was collected. The protein concentra-
tion was estimated by the method of Bradford (8), and aliquots of 500 l were
stored at 70°C.
LRP was prepared from logarithmic-phase promastigotes of L. infantum, as
described previously (28). Briefly, 1 109 promastigotes were harvested, washed
twice in prechilled PBS, resuspended in 1 ml Nonidet P-40 lysis buffer (10 mM
Tris HCl, pH 8.0, 150 mM NaCl, 1.5 mM MgCl2, 0.5% Nonidet P-40), and
pipetted up and down 10 times. After lysis, the samples were centrifuged on a
Microfuge at 3,000  g for 2 min at 4°C to pellet the nuclei. The supernatant was
twice centrifuged on a Microfuge at 13,000  g for 15 min at 4°C. The purified
cytosolic supernatant was submitted to high-speed centrifugation at 90,000 rpm
for 30 min at 4°C in a Beckman TL100.3 rotor. The crude ribosomal pellet was
resuspended in buffer A (20 mM Tris-HCl, pH 7.4, 500 mM ammonium acetate,
100 mM MgCl2, 5 mM -mercaptoethanol) and centrifuged through a discon-
tinuous sucrose gradient (20/40%) in buffer A at 90,000 rpm and 4°C in a
TL100.3 rotor. The pellet of washed ribosomes was dissolved in PBS, sonicated,
and stored at 70°C. The LRP concentration was estimated by the method of
Bradford (8).
Serum samples. Serum samples were collected in Spain and Brazil. Serum
samples were collected from 28 clinically symptomatic dogs with CVL in the
Extremadura region of Spain. L. infantum-infected animals were clinically, im-
munologically, and parasitologically evaluated at the Department of Parasitology
of the Veterinary School, Extremadura University, Ca´ceres, Spain. The animals
were considered symptomatic when three or more of the following symptoms
were present: loss of weight; alopecia; adenopathy; onychogryposis; hepatomeg-
aly; conjunctivitis; and exfoliative dermatitis on the nose, tail, and ear tips. All
serum samples were positive when they were tested by indirect immunofluores-
cence, as described previously (10). The presence of amastigote forms was
confirmed by direct observation in popliteal and prescapular lymph nodes. Con-
trol sera were obtained from eight healthy animals that had been bred and
maintained in an experimental kennel under defined conditions at the Depart-
ment of Parasitology (Extremadura University).
Serum samples from 83 L. chagasi-infected dogs (44 clinically symptomatic, 17
oligosymptomatic, and 22 asymptomatic dogs) from the Belo Horizonte area,
Minas Gerais, Brazil, were used. The animals were considered symptomatic
when they presented with three or more of the clinical symptoms described
above, were considered oligosymptomatic when only one or two symptoms were
present, and were considered asymptomatic when the dogs were free from
clinical symptoms. Diagnosis of the disease was defined when amastigotes were
seen in Giemsa-stained smears of bone marrow aspirates or promastigotes were
identified on culture of peripheral blood or bone marrow aspirates. Fourteen
serum samples from dogs with other parasite infections were used to analyze
cross-reactivity, as follows: Toxoplasma gondii (n  5) and Trypanosoma cruzi
(n  9). These sera were provided by Evaldo Nascimento and Maria Norma
Melo (Department of Parasitology, Institute of Biological Sciences, Univer-
sidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil). Serum
samples from 47 dogs that were living in regions where visceral leishmaniasis
(VL) is endemic but that had no clinical signs or suspicion of CVL and that were
negative after parasitological and serological tests constituted the control group.
Serum samples from healthy dogs and from dogs vaccinated with the Leishmune
vaccine (n  18) or the Leishtec vaccine (n  23) were used to analyze their
reactivity with LRPs and the SLA.
ELISA. Microtiter immunoassay plates (Falcon) were coated with L. infantum
or L. chagasi SLA or with L. infantum LRPs (each one at 0.5 g/well) in coating
buffer (pH 9.6) for 18 h at 4°C. A titration curve was prepared to determine the
best protein concentration (for LRPs, 4 g to 0.063 g; for SLA, 2 g to 0.031
g) and the best antibody dilution to be used. Free binding sites were blocked
with a PBS–0.05% Tween 20 (PBST) and 3% casein solution for 2 h at 37°C.
After three washes with PBST, the plates were incubated with 100 l of canine
serum for 1 h at 37°C. Serum samples were diluted 1:200 in PBST and 0.3%
casein. The plates were then washed seven times and incubated with horseradish
peroxidase-conjugated 1:10,000 anti-dog immunoglobulin G (IgG) antibody
(Sigma). The reaction developed through incubation with H2O2, ortho-phenyl-
enediamine, and citrate-phosphate buffer (pH 5.0) for 30 min in the dark and was
stopped by addition of 2 N H2O2. The optical densities were read at 492 nm in
an ELISA microplate spectrophotometer (Spectra Max Plus; Molecular Devices,
Concord, Ontario, Canada).
Western blotting. For Western blot analysis, L. infantum SLA (15 g) and
LRPs (15 g) were resuspended in Laemmli’s buffer and resolved in a 10%
(SLA) or a 10 to 14% gradient (LRP) sodium dodecyl sulfate (SDS)-polyacryl-
amide gel with preparative combs by using a Bio-Rad (Hercules, CA) protein
electrophoresis minigel system. In both cases, the gels were transferred to nitro-
cellulose membranes (GE Healthcare). The blots were probed individually with
the sera (1:200) from dogs infected with L. infantum (by SDS-polyacrylamide gel
electrophoresis). As the secondary antibody, horseradish peroxidase-conjugated
anti-dog IgG (1:2,000) purchased from Nordic Immunological Laboratories (Til-
burg, The Netherlands) was used.
Statistical analysis. Statistical analysis was performed with GraphPad Prism
software (version 4 for Windows). The reactivities of the serum samples collected
in Spain against SLA and LRPs were tested for significance by using the Mann-
Whitney test. The reactivities of the serum samples collected in Brazil against
SLA and LRPs were evaluated by means of the one-way analysis of variance
nonparametric test (Kuskal-Wallis by using the Dunn posttest for multiple com-
parisons of groups). P values of 0.05 were considered statistically significant.
RESULTS
Antigenicity of LRPs during canine infection. In order to
analyze the antigenicity of the LRPs during canine infection,
sera from 10 dogs clinically infected with L. infantum that
recognized a large number of protein bands in the SLA ex-
tracts (Fig. 1A, SLA panel, lanes 4 to 13) were incubated with
a nitrocellulose membrane containing the LRP extracts from
this species. All serum samples from dogs with symptomatic
CVL recognized the parasite ribosomal purified protein frac-
tion (Fig. 1A, panel LRP, lanes 4 to 13). The sera from healthy
dogs were negative, and only a few protein bands were slightly
stained in the LRP and SLA preparations (Fig. 1A, lanes 1 to
3). Most of the serum samples from dogs with symptomatic
CVL recognized several protein bands in both protein extracts,
although the complexity and intensity of the recognition pat-
tern were different between the serum samples from individual
dogs. Despite the variability obtained, two immunodominant
regions were observed in the LRP Western blot: 45- to 36-kDa
and 25- to 22-kDa proteins. The immunoreactivities of sera
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from dogs clinically infected with L. infantum against LRP and
SLA were measured by ELISA. Figure 1B shows the absor-
bance values for the sera from dogs with symptomatic CVL
(n  28) and the controls (n  8) collected in Spain. For both
protein preparations, sera from 100% of the dogs with symp-
tomatic CVL showed absorbance values above the cutoff, and
the differences in the mean value of the reactivity between the
sera from dogs with symptomatic CVL and control sera were
statistically significant.
Comparison of LRPs and SLA for serodiagnosis of CVL.
Since antibodies reacting against LRP were observed in the
sera from dogs with symptomatic CVL due to L. infantum
infection, we analyzed whether the L. infantum LRP extract
could be considered a valuable tool for the serodiagnosis of
CVL in other regions of the world. For that purpose, we
analyzed the reactivity against L. infantum LRPs and L. chagasi
SLA of 130 canine serum samples collected in a region of
Brazil that is endemic for CVL due to infection by Leishmania
chagasi. Those samples included sera from dogs infected with
L. chagasi with symptomatic infections (n  44), oligosymp-
tomatic infections (n  17), and asymptomatic infections (n 
22), as well as 47 healthy dogs living in that area of endemicity.
For both protein preparations, the differences between the
mean of the absorbance values observed for sera from dogs
with symptomatic CVL and healthy control sera were statisti-
cally significant (P  0.001) (Fig. 2). The spectrum of the
absorbance values from the LRPs and SLA were different, as
the reactivity of sera from dogs with CVL against SLA was
higher (mean, 1.58  0.10) than that of sera from dogs with
CVL against LRP (mean, 0.64  0.28). The reactivity of the
healthy sera was also higher against SLA (mean, 0.41  0.1)
than against LRP (mean, 0.09  0.04). The cutoff values (de-
fined as the mean reactivity value from healthy sera plus 3
standard deviations) were 0.213 for LRPs and 0.735 for SLA.
These cutoff values allowed us to identify positive and negative
sera and, consequently, to estimate the performance parame-
ters of the ELISA for the diagnosis of symptomatic CVL (Ta-
ble 1). When the sera from oligosymptomatic and asymptom-
atic dogs were included in the analysis, ELISA with LRPs gave
the best results in terms of sensitivity: 100% for both groups
(P  0.001; the mean of the absorbance values observed for
sera from oligosymptomatic and asymptomatic dogs compared
with the mean of the absorbance value for sera from healthy
dogs) (Fig. 2). On the other hand, the SLA-based ELISA was
only 59% sensitive (10/17) with sera from oligosymptomatic
dogs (P  0.01; the mean of the absorbance values observed
for sera from oligosymptomatic dogs compared with the mean
of the absorbance value for sera from healthy dogs). In addi-
tion, the SLA-based ELISA detected considerably fewer
asymptomatic cases (19%; 4/22) than the LRP-based ELISA,
with no statistically significant differences in the mean of the
absorbance values for these sera and the mean of the absor-
bance for sera from healthy dogs being observed (Fig. 2).
Cross-reactivity of LRPs and SLA. Since LRP is composed
of evolutive conserved proteins in Leishmania, we have ana-
lyzed the potential cross-reactions of the LRP extracts with the
sera from dogs infected with other unicellular protozoa: Toxo-
plasma gondii (n  5) and Trypanosoma cruzi (n  9). In Fig.
FIG. 1. (A) Leishmania infantum LRPs were electrophoresed on a linear 10 to 14% gradient SDS-polyacrylamide gel. Leishmania infantum
SLA was electrophoresed on a 10% SDS-polyacrylamide gel. Both gels were transferred onto nitrocellulose membranes and incubated with sera
from healthy dogs maintained in an experimental kennel under defined conditions (lanes 1 to 3) and sera from dogs naturally infected with L.
infantum and with symptomatic CVL (lanes 4 to 13). The individual serum samples were used at a 1:200 dilution. A horseradish peroxidase-
conjugated anti-dog IgG antibody was used as the secondary reagent. (B) ELISA reactivity of sera collected in Spain from dogs clinically infected
with L. infantum and control sera with LRPs and SLA. Solid lines, mean values; dotted lines, cutoff value, defined as the mean optical density plus
3 standard deviations of the values obtained with sera from healthy controls. Abs, absorbance; **, P  0.01; ***, P  0.001.
1776 COELHO ET AL. CLIN. VACCINE IMMUNOL.
 at CSIC-PUBLICACIO
NES ELECTRO
NICAS on Novem
ber 30, 2009 
cvi.asm
.org
D
ow
nloaded from
 
3A, the reactivity values of the individual sera for each group
against LRPs are shown. None of the sera from the T. gondii-
infected dogs (mean, 0.1012  0.056) or the T. cruzi-infected
dogs (mean, 0.101  0.06) showed reactivity above the cutoff
defined by the sera from healthy dogs. When the reactivities of
these two groups of sera to LRPs were compared with the
responses shown by the sera from the healthy dogs, there were
no statistically significant differences (Fig. 3A). On the other
hand, the mean reactivities of these sera against SLA (0.629 
0.21 for T. gondii-infected dogs and 0.99  0.29 for T. cruzi-
infected dogs) were higher than those observed against LRPs,
with some of the absorbance values being above the cutoff (two
of five serum samples for T. gondii-infected dogs and eight of
nine serum samples for T. cruzi-infected dogs). Yet the reac-
tivity against SLA of the sera from the T. cruzi-infected dogs
was statistically significantly different (P  0.05) compared
with the reactivity against SLA of the sera from healthy dogs
(Fig. 3A).
Finally, the reactivities of the sera from dogs vaccinated with
two Leishmania prophylactic vaccines licensed in Brazil, Leish-
mune (39) and Leishtec (19), against the LRP and SLA ex-
tracts were assayed. Although there were no statistically sig-
nificant differences between the sera from Leishmune- or
Leishtec-vaccinated dogs and the sera from the healthy control
dogs, we found that 22.2% (4/18) of the serum samples from
dogs vaccinated with Leishmune showed absorbance values
above the cutoff when the LRP extracts were used in the
ELISAs (Fig. 3B). When the sera from the Leishmune-vacci-
nated dogs were analyzed in the SLA-based ELISAs, the same
percentage (22.2%; 4/18) showed reactivity values above the
cutoff, with 3 of these 4 serum samples being the same samples
that showed cross-reactivity with LRPs. None of the 23 serum
samples obtained from dogs vaccinated with Leishtec showed
reactivity against SLA. Only one of these serum samples
showed reactivity against LRPs and had an optical density
value close to the cutoff defined by the negative sera from the
healthy controls. When the reactivities of these two groups of
serum samples to LRPs and SLA were compared, the mean
absorbance values were higher for the SLA extracts (0.52 
0.24 for Leishmune and 0.19  0.1 for Leishtec) than for the
LRP extracts (0.24  0.13 for Leishmune and 0.08  0.04 for
Leishtec).
DISCUSSION
As occurs with other Leishmania intracellular proteins, such
as histones, cysteine proteinases, or kinesine (3, 14, 15, 41, 43,
46), we show in this work that during CVL many of the ribo-
some constituents are antigenic proteins. Since the antigenicity
of the parasite ribosomal proteins was also demonstrated in
mouse models of cutaneous leishmaniasis (28), it can be de-
duced that parasite ribosomes interact with the immune system
of the vertebrate hosts during natural and experimental Leish-
mania infections. Parasite ribosomal proteins were employed
as the source of antigen for ELISA, a precise and sensitive
technique for the screening of a large number of samples for
the diagnosis of VL (21, 44). A comparative analysis of the
LRP extracts and total parasite proteins obtained from pro-
mastigote lysates was performed because the use of crude
FIG. 2. Comparative evaluation of the diagnostic sensitivities of the Leishmania infantum LRPs and the Leishmania chagasi SLA. The
reactivities of sera collected from dogs with symptomatic, oligosymptomatic, and asymptomatic CVL against LRPs and SLA were analyzed by
ELISA. As a control, the reactivities of sera from healthy (uninfected) dogs living in regions where VL is endemic against LRPs and SLA were
measured. Solid lines, mean values of reactivity for different groups of sera; dotted lines, cutoff value, defined as the mean optical density plus 3
standard deviations of the values obtained with sera from healthy controls. Abs, absorbance; Olig, oligosymptomatic CVL; Asymp, asymptomatic
CVL; **, P  0.01; ***, P  0.001; NS, not significant (P  0.05).
TABLE 1. Sensitivities and specificities of ELISAs with LRPs and
SLA for serodiagnosis of symptomatic dogs infected
with L. chagasi
Antigen Sensitivity
a
(%)
Specificityb
(%) PPV
c (%) NPVd (%)
LRP 100 (0/44) 98.2 (1/47) 97.70 100
SLA 96 (3/44) 100 (0/47) 100 94
a Sensitivity was calculated from the equation number of true-positive sam-
ples/(number of true-positive samples 	 number of false-negative samples)
 
100. The number of samples with false-negative results/total number of samples
tested is indicated in parentheses.
b Specificity was calculated from the equation number of true-negative sam-
ples /(number of true-negative samples 	 number of false-positive samples)
 
100. The number of samples with false-positive results/total number of samples
tested is indicated in parentheses.
c PPV, positive predictive value, which was calculated from the equation num-
ber of true-positive samples/(number of true-positive samples 	 number of
false-positive samples)
  100.
d NPV, negative predictive value, which was calculated from the equation
number of true-negative samples/(number of true-negative samples 	 number
of false-negative samples)
  100.
VOL. 16, 2009 SERODIAGNOSIS OF CANINE VISCERAL LEISHMANIASIS 1777
 at CSIC-PUBLICACIO
NES ELECTRO
NICAS on Novem
ber 30, 2009 
cvi.asm
.org
D
ow
nloaded from
 
SLA-based ELISAs has usually provided a high degree of
sensitivity for the diagnosis of VL (6, 31, 44).
By using sera from dogs with symptomatic CVL in a region
of Brazil where VL is endemic, the sensitivity and specificity
values obtained with the LRP extracts were similar to those
shown by the use of SLA when the sera from healthy dogs
obtained in the same region were employed as a control. A
slight increase in sensitivity was obtained with LRP compared
with that achieved with SLA (100% and 96%, respectively),
and only one of the serum samples obtained from healthy dogs
showed an absorbance value against LRP above the cutoff
defined by the reactivity of the control sera. In addition, 100%
of the serum samples from oligosymptomatic dogs assayed had
a positive reaction against LRP, but only 59% were found to be
positive when SLA was used. Thus, it can be concluded that the
diagnostic performance of the LRP-based ELISA was similar
to that of the SLA-based ELISA for the diagnosis of symp-
tomatic CVL. In addition, the sensitivity of the LRP-based
ELISA was higher than that of the SLA-based ELISA for the
diagnosis of oligosymptomatic CVL.
Serodiagnosis is usually carried out to confirm the presence
of CVL in dogs presenting with clinical manifestations (4, 26).
However, the detection of asymptomatic dogs may be critical
in epidemiological studies for controlling the spread of the
disease among dogs and also between dogs and humans, since
seropositive asymptomatic dogs have been implicated in the
transmission of the parasite to the insect vector (18, 33, 36).
Since the SLA-based ELISA failed to detect a large percentage
of asymptomatic cases of CVL (34, 42), we analyzed the sen-
sitivity of the LRP extracts for the diagnosis of asymptomatic
CVL. Whereas the LRP antigen mixture detected all the
asymptomatic cases (100%), the assay with the SLA prepara-
tion detected only about 19% of the cases. Although the reac-
tivity against LRP needs further confirmation by use of a larger
number of serum samples from asymptomatic dogs, the use of
LRP-based ELISAs in combination with other proposed par-
asitological, cellular, and serological tests may be useful for the
detection of asymptomatic dogs in areas of endemicity (11, 38).
In addition, we are analyzing the correlation between serore-
activity against LRP and the transmission of the parasites to
the insect vector, as well as the clinical evolution of LRP-
positive asymptomatic dogs.
The specificity of the ELISA with SLA largely depends on
the antigen preparation, and some false-positive results were
obtained with the sera collected from patients or dogs with
diseases that are coendemic with VL or CVL, such as Chagas’
disease, malaria, leprosy, and toxoplasmosis (21, 29, 42). For
this reason, several parasitic recombinant proteins have been
individually employed as the antigen in ELISAs for the devel-
opment of a more specific diagnostic test (30). Comparative
ELISAs generally revealed higher specificities but lower sen-
sitivities when individual recombinant antigens instead of SLA
were employed for the diagnosis of human VL (31) or CVL
(42). Lower sensitivity values were related to the variability in
the heterogeneous humoral response elicited against parasite
proteins observed in each patient or infected dog. The use of a
combination of nonrelated antigens (25, 42) or the production
of polyproteins containing several parasite antigens (7, 49)
FIG. 3. Comparative evaluation of the diagnostic specificity of Leishmania infantum LRPs and Leishmania chagasi SLA. (A) ELISA
reactivities of sera from dogs infected with T. gondii or T. cruzi with LRPs and SLA. (B) ELISA reactivities of sera from dogs vaccinated
with the Leishmune or the Leishtec vaccine with LRPs and SLA. As a control, the reactivities of sera from healthy (uninfected) dogs living
in regions where VL is endemic against LRPs and SLA were measured. Solid lines, mean value of the reactivity; dotted lines, cutoff value,
defined as the mean optical density plus 3 standard deviations of the values obtained with sera from healthy controls. Abs, absorbance; *, P 
0.05; NS, not significant (P  0.05).
1778 COELHO ET AL. CLIN. VACCINE IMMUNOL.
 at CSIC-PUBLICACIO
NES ELECTRO
NICAS on Novem
ber 30, 2009 
cvi.asm
.org
D
ow
nloaded from
 
could further improve the performance of the ELISAs. Alter-
natively, purified parasite fractions containing different para-
site antigens have been shown to be an alternative for the
development of sensitive and specific tests for the diagnosis of
CVL (6). Since the sera from T. cruzi- or T. gondii-infected
dogs were not able to recognize LRP extracts, whereas some of
these sera showed a high degree of reactivity against SLA, our
data indicate that LRP can be employed as a more specific
antigen than SLA for the differential diagnosis of CVL.
In order to define the composition of future diagnostic tests
based on parasite ribosomal proteins, we are now characteriz-
ing the main antigenic components of the parasite ribosomes.
The use of these molecules in combination with other parasite
recombinant antigens recognized by sera from different per-
centages of symptomatic and asymptomatic dogs with CVL,
such as rK39 (25), A2 (13), and tryparedoxin peroxidase (47),
may promote the development of more specific and sensitive
tests for the diagnosis of CVL.
The diagnostic specificity of the test should also be main-
tained when sera are obtained from vaccinated dogs. Due to
the existence of licensed commercial vaccines in Brazil (19,
39), it would be desirable to differentiate infected dogs from
vaccinated animals. Our results show that while some of the
serum samples from animals vaccinated with Leishmune
showed some reactivity against LRPs and SLA, the sera from
none of the animals vaccinated with Leishtec reacted against
these antigenic preparations. Palatnik-de-Sousa et al. (40) have
described the protective effect of the fucose-mannose ligand
vaccine, like the Leishmune vaccine, against CVL. As expected
with the use of saponin adjuvants, the Leishmune vaccine in-
duces a strong humoral immune response soon after the com-
plete vaccination is provided (9). Therefore, an indistinct IgG-
mediated anti-L. chagasi immune response is detected in
Leishmune-vaccinated dogs, and that response is indistinct
from that due to natural infection with L. chagasi. This fact can
explain the reactivity of some serum samples obtained when
Leishmania antigens (LRPs and SLA) were used in the
ELISAs.
Taken together, the results presented here demonstrate that
the LRP extracts may be considered an interesting alternative
for use for the diagnosis of CVL by ELISA, mainly in asymp-
tomatic animals, in epidemiological studies in areas of ende-
micity.
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